Get the Stockscreener App
25.39
46.61%
-22.16
Dice Therapeutics Inc stock is traded at $25.39, with a volume of 105.
It is down -46.61% in the last 24 hours and down -46.61% over the past month.
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is S011806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
See More
Previous Close:
$47.55
Open:
$25.69
24h Volume:
105
Relative Volume:
66.00
Market Cap:
$2.27B
Revenue:
-
Net Income/Loss:
$-104.24M
P/E Ratio:
-10.85
EPS:
-2.34
Net Cash Flow:
$-87.22M
1W Performance:
-46.61%
1M Performance:
-46.61%
6M Performance:
-46.61%
1Y Performance:
-46.61%
1-Day Range:
$25.69
$25.69
1-Week Range:
$25.69
$25.69
52-Week Range:
$25.69
$25.69
Dice Therapeutics Inc Stock (DICE) Company Profile
Name
Dice Therapeutics Inc
Sector
Industry
Phone
650-566-1402
Address
279 East Grand Avenue, Suite 300 Lobby B, South San Francisco
Compare DICE vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DICE
Dice Therapeutics Inc
|
25.69 | 2.27B | 0 | -104.24M | -87.22M | -2.34 |
VRTX
Vertex Pharmaceuticals Inc
|
522.09 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.91 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,002.40 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.63 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.24 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dice Therapeutics Inc Stock (DICE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-23 | Initiated | Needham | Buy |
| Mar-01-23 | Initiated | Cowen | Outperform |
| Mar-01-23 | Initiated | TD Cowen | Outperform |
| Nov-15-22 | Initiated | Guggenheim | Buy |
| Sep-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Evercore ISI | Outperform |
| Oct-11-21 | Initiated | SVB Leerink | Outperform |
View All
Dice Therapeutics Inc Stock (DICE) Latest News
DICE Therapeutics Inc. (DICE) Peer Comparison – Compare with Others - Value Research
Ambros Therapeutics Announces Appointments of John C. Jacobs and Scott Robertson to Board of Directors - The Manila Times
Autoimmune Treatment Market Report Examines Industry Trends, Growth Drivers And Future Outlook - openPR.com
DHI Group (DHX) Stock Sees Fair Value Lift As Analysts Weigh ClearanceJobs And Dice - Yahoo Finance
Segment Overview and Major Growth Areas in the Urokinase Market - openPR.com
CAPR Stock Drop: Capricor Therapeutics Clinical Data Leads to 64% Stock Drop and Securities Fraud Class Action for Investors - PR Newswire
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology - Eli Lilly and Company
A 'Made in the USA' Monopoly edition cost twice as much to build — and no US factory could even make the dice - Yahoo Finance
An InventHelp 123Invent Client Develops New Money Themed Dice Game (LBT-9813) - Yahoo Finance
The EU rolls dice by setting unambiguous parameters for Satcos operating in 2GHz - Yahoo Finance
Tech Professionals Find Relevant Roles Faster with Dice’s LLM Connector - Yahoo Finance
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188% - The Motley Fool
Morningstar Sees SpaceX Worth Half Its IPO Price - thedeepdive.ca
OpenAI Files Confidential S-1 With SEC, Targeting IPO as Soon as Q4 - thedeepdive.ca
SpaceX Cuts IPO Valuation Target to $1.8 Trillion After Investor Feedback - TheDeepDive.ca
TWO DICE SECURES STRATEGIC INVESTMENT FROM OAK VIEW GROUP - Yahoo Finance
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire
Russia is about to roll the dice on crypto regulation. Here’s its playbook - Yahoo Finance
Jim Cramer on JetBlue Airways: “It’s a Dice Roll, and I Don’t Like Dice Rolls” - Yahoo Finance
EA Slashes Battlefield Headcount In a Pivot to AI - Yahoo Finance
Burnout, layoffs, 'ghost jobs' in Dice's 2026 tech survey - Stock Titan
Muted and missing M&As: JPM deals absent in 2026 - bioworld.com
Baron of Dice Answers the Questions Players Keep Asking - Yahoo Finance
Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs - BioPharma Dive
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing - Seeking Alpha
Boyd Gaming reveals $160M revamp for Par-A-Dice Casino - Yahoo Finance
IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes - American Heart Association Journals
Journal of the European Academy of Dermatology and Venereology - Wiley Online Library
Don't Buy Summit Therapeutics Until This Big Thing Happen - The Motley Fool
Big pharma drives surge in biopharma job cuts in 2025 - BioWorld News
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy - Business Wire
RNA Therapeutics Market Size to Reach USD 26.13 Billion by 2034 - BioSpace
Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight - PR Newswire
Formulation specialist Azurity to lay off 75 amid plans to sunset Massachusetts plant - Fierce Pharma
Fever Acquires Ticketing Platform Dice - Yahoo Finance
Forward Therapeutics, the first biotech from Curie.Bio, raises $50M for oral small molecules in immunology - Endpoints News
DHI Group Inc (DHX) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Focus - Yahoo Finance
15 Best Growth Stocks to Buy for the Next 3 Years - Insider Monkey
Dice Therapeutics Stock Price, News & Analysis - Stock Titan
Biopharma restructurings reflect strategy of short-term pain for long-term gains - BioWorld News
10 Best Low Volatility Stocks to Buy Now - Insider Monkey
The top 10 pharma R&D budgets for 2024 - Fierce Biotech
Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25) - GlobeNewswire
Sage lawsuit enforces standstill as board evaluates Biogen offer - BioWorld News
The top 10 biopharma M&A deals of 2024 - Fierce Pharma
Gambling.com Rolls The Dice On OddsJam's Parent; $80M Upfront Consideration For Instant Revenue Boost - Yahoo Finance
Combos, New MOAs, And Oral Formulations Of Injectables: Lilly’s Immunology Strategy - insights.citeline.com
Why Did Eli Lilly Stock Fall 6%? - Trefis
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products - Eli Lilly and Company
Mounjaro To Lead Eli Lilly’s Q3 Growth - Trefis
Dice Therapeutics Inc Stock (DICE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
0.62%
Cap:
|
Volume (24h):